We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01325350
Recruitment Status : Completed
First Posted : March 29, 2011
Results First Posted : April 9, 2014
Last Update Posted : April 9, 2014
Sponsor:
Information provided by (Responsible Party):
Allergan

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions Alopecia
Baldness
Interventions Drug: bimatoprost Formulation A
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C
Drug: bimatoprost vehicle solution
Drug: minoxidil 2% solution
Enrollment 306
Recruitment Details  
Pre-assignment Details  
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description Approximately one milliliter (mL) of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of minoxidil 2% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Period Title: Overall Study
Started 61 61 61 61 62
Completed 55 56 44 52 50
Not Completed 6 5 17 9 12
Reason Not Completed
Adverse Event             3             3             3             1             2
Pregnancy             0             0             1             0             1
Lost to Follow-up             1             0             5             1             5
Personal Reasons             2             1             6             5             3
Protocol Violation             0             0             0             1             0
Withdrawal by Subject             0             0             1             1             0
Did Not Receive Treatment             0             1             1             0             1
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution Total
Hide Arm/Group Description Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months. Total of all reporting groups
Overall Number of Baseline Participants 61 61 61 61 62 306
Hide Baseline Analysis Population Description
[Not Specified]
Age, Customized  
Measure Type: Number
Unit of measure:  Participants
 Number Analyzed 61 participants 61 participants 61 participants 61 participants 62 participants 306 participants
18 to 34 years 12 13 12 13 12 62
35 to 59 years 49 48 49 48 50 244
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 61 participants 61 participants 61 participants 61 participants 62 participants 306 participants
Female
61
 100.0%
61
 100.0%
61
 100.0%
61
 100.0%
62
 100.0%
306
 100.0%
Male
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
1.Primary Outcome
Title Change From Baseline in Target Area Hair Count (TAHC)
Hide Description TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). A negative change from Baseline indicated worsening (decrease in the number of terminal hairs).
Time Frame Baseline, Month 6
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description:
Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Overall Number of Participants Analyzed 61 60 60 61 61
Mean (Standard Deviation)
Unit of Measure: terminal hairs/cm^2
Baseline 153.1  (54.78) 161.1  (63.85) 145.2  (63.42) 163.0  (57.28) 156.3  (55.46)
Change from Baseline at Month 6 -0.4  (17.10) -3.5  (18.21) 4.3  (16.82) 1.1  (20.44) 13.6  (18.72)
2.Primary Outcome
Title Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score
Hide Description The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: "Since the start of the study, the amount of my hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
Time Frame Baseline, Month 6
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description:
Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Overall Number of Participants Analyzed 58 60 54 61 56
Measure Type: Number
Unit of Measure: Percentage of participants
Greatly Increased 3.4 3.3 9.3 3.3 7.1
Moderately Increased 17.2 20.0 16.7 18.0 28.6
Slightly Increased 34.5 21.7 16.7 24.6 35.7
Remained the Same 20.7 33.3 38.9 29.5 19.6
Slightly Decreased 19.0 11.7 13.0 13.1 5.4
Moderately Decreased 1.7 8.3 5.6 8.2 1.8
Greatly Decreased 3.4 1.7 0.0 3.3 1.8
3.Secondary Outcome
Title Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score
Hide Description The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: "Since the start of the study, the amount of the subject's hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
Time Frame Baseline, Month 6
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description:
Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Overall Number of Participants Analyzed 58 60 54 61 56
Measure Type: Number
Unit of Measure: Percentage of participants
Greatly Increased 5.2 3.3 7.4 1.6 1.8
Moderately Increased 12.1 10.0 11.1 14.8 16.1
Slightly Increased 24.1 35.0 25.9 23.0 37.5
Remained the Same 39.7 40.0 51.9 54.1 41.1
Slightly Decreased 15.5 10.0 3.7 6.6 3.6
Moderately Decreased 3.4 1.7 0.0 0.0 0.0
Greatly Decreased 0.0 0.0 0.0 0.0 0.0
4.Secondary Outcome
Title Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score
Hide Description At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: "Compared with the baseline image, the amount of the subject's hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
Time Frame Baseline, Month 6
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description:
Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Overall Number of Participants Analyzed 55 59 48 61 53
Measure Type: Number
Unit of Measure: Percentage of participants
Greatly Increased 0.0 0.0 0.0 0.0 0.0
Moderately Increased 1.8 0.0 2.1 1.6 0.0
Slightly Increased 0.0 6.8 6.3 6.6 17.0
Remained the Same 87.3 81.4 81.3 88.5 79.2
Slightly Decreased 10.9 11.9 10.4 3.3 1.9
Moderately Decreased 0.0 0.0 0.0 0.0 1.9
Greatly Decreased 0.0 0.0 0.0 0.0 0.0
5.Secondary Outcome
Title Change From Baseline in Target Area Hair Width (TAHW)
Hide Description Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). A negative change from Baseline indicated worsening (decrease in the diameter of terminal hairs).
Time Frame Baseline, Month 6
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description:
Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Overall Number of Participants Analyzed 61 60 60 61 61
Mean (Standard Deviation)
Unit of Measure: mm/cm^2
Baseline 8.92  (3.444) 9.64  (3.308) 8.86  (3.977) 10.13  (4.165) 9.76  (3.698)
Change from Baseline from Month 6 0.13  (1.198) -0.19  (1.067) 0.30  (1.263) 0.07  (1.183) 0.87  (1.315)
6.Secondary Outcome
Title Change From Baseline in Target Area Hair Darkness (TAHD)
Hide Description Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs).
Time Frame Baseline, Month 6
Hide Outcome Measure Data
Hide Analysis Population Description
Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description:
Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.
Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Overall Number of Participants Analyzed 61 60 60 61 61
Mean (Standard Deviation)
Unit of Measure: Intensity units
Baseline 95.63  (23.837) 100.12  (25.077) 92.76  (19.433) 96.90  (22.678) 93.07  (20.667)
Change from Baseline at Month 6 2.94  (13.084) 4.22  (13.159) 2.11  (14.674) 2.07  (11.486) 2.12  (11.561)
Time Frame [Not Specified]
Adverse Event Reporting Description The Safety Population (all participants who received at least 1 dose of study treatment) was used to calculate the number of participants at risk for treatment-emergent Serious Adverse Events and treatment-emergent Adverse Events.
 
Arm/Group Title Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Hide Arm/Group Description Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months. Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
All-Cause Mortality
Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/--   --/--   --/--   --/-- 
Hide Serious Adverse Events
Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   4/61 (6.56%)   4/60 (6.67%)   3/60 (5.00%)   1/61 (1.64%)   1/61 (1.64%) 
General disorders           
Death † 1 [1]  0/61 (0.00%)  0/60 (0.00%)  1/60 (1.67%)  0/61 (0.00%)  0/61 (0.00%) 
Hepatobiliary disorders           
Cholecystitis † 1 [1]  0/61 (0.00%)  1/60 (1.67%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Infections and infestations           
Appendicitis † 1 [1]  0/61 (0.00%)  1/60 (1.67%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Gastroenteritis † 1 [1]  0/61 (0.00%)  0/60 (0.00%)  1/60 (1.67%)  0/61 (0.00%)  0/61 (0.00%) 
Musculoskeletal and connective tissue disorders           
Osteoarthritis † 1 [2]  2/61 (3.28%)  0/60 (0.00%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Arthralgia * 1 [1]  0/61 (0.00%)  1/60 (1.67%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Rotator cuff syndrome † 1 [1]  0/61 (0.00%)  1/60 (1.67%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Intervertebral disc protrusion † 1 [2]  0/61 (0.00%)  0/60 (0.00%)  1/60 (1.67%)  1/61 (1.64%)  0/61 (0.00%) 
Chondropathy † 1 [1]  0/61 (0.00%)  0/60 (0.00%)  0/60 (0.00%)  0/61 (0.00%)  1/61 (1.64%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)           
Benign ovarian tumour † 1 [1]  0/61 (0.00%)  1/60 (1.67%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Nervous system disorders           
Syncope * 1 [1]  1/61 (1.64%)  0/60 (0.00%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
Respiratory, thoracic and mediastinal disorders           
Pneumothorax † 1 [1]  1/61 (1.64%)  0/60 (0.00%)  0/60 (0.00%)  0/61 (0.00%)  0/61 (0.00%) 
†
Indicates events were collected by systematic assessment
*
Indicates events were collected by non-systematic assessment
1
Term from vocabulary, MedDRA (15.0)
[1]
Event not treatment-related
[2]
Events not treatment-related
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Bimatoprost Formulation A Bimatoprost Formulation B Bimatoprost Formulation C Vehicle to Bimatoprost Minoxidil 2% Solution
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   17/61 (27.87%)   17/60 (28.33%)   15/60 (25.00%)   20/61 (32.79%)   24/61 (39.34%) 
General disorders           
Application site pruritis * 1  0/61 (0.00%)  3/60 (5.00%)  2/60 (3.33%)  0/61 (0.00%)  5/61 (8.20%) 
Application site dryness * 1  1/61 (1.64%)  1/60 (1.67%)  0/60 (0.00%)  2/61 (3.28%)  4/61 (6.56%) 
Infections and infestations           
Upper respiratory tract infection † 1  6/61 (9.84%)  5/60 (8.33%)  0/60 (0.00%)  1/61 (1.64%)  2/61 (3.28%) 
Nasopharyngitis † 1  1/61 (1.64%)  2/60 (3.33%)  2/60 (3.33%)  6/61 (9.84%)  7/61 (11.48%) 
Sinusitis † 1  1/61 (1.64%)  3/60 (5.00%)  1/60 (1.67%)  2/61 (3.28%)  1/61 (1.64%) 
Injury, poisoning and procedural complications           
Procedural pain * 1  2/61 (3.28%)  1/60 (1.67%)  3/60 (5.00%)  2/61 (3.28%)  1/61 (1.64%) 
Nervous system disorders           
Headache * 1  1/61 (1.64%)  1/60 (1.67%)  4/60 (6.67%)  5/61 (8.20%)  1/61 (1.64%) 
Skin and subcutaneous tissue disorders           
Hypertrichosis * 1  5/61 (8.20%)  1/60 (1.67%)  0/60 (0.00%)  1/61 (1.64%)  3/61 (4.92%) 
Vascular disorders           
Hypertension † 1  0/61 (0.00%)  0/60 (0.00%)  3/60 (5.00%)  1/61 (1.64%)  0/61 (0.00%) 
†
Indicates events were collected by systematic assessment
*
Indicates events were collected by non-systematic assessment
1
Term from vocabulary, MedDRA (15.0)
[Not Specified]
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Therapeutic Area Head,
Organization: Allergan, Inc
Phone: 714-246-4500
EMail: clinicaltrials@allergan.com
Layout table for additonal information
Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01325350    
Other Study ID Numbers: 192024-058
2011-000380-27 ( EudraCT Number )
First Submitted: March 28, 2011
First Posted: March 29, 2011
Results First Submitted: March 3, 2014
Results First Posted: April 9, 2014
Last Update Posted: April 9, 2014